文献速递骨肿瘤关节外科

非侵入性可延长假体在翻修关节置换术中的应用

The use of a non-invasive extendable prosthesis at the time of revision arthroplasty.
PubMed 文献 · Bone Joint J · 2018-01-01

本研究回顾了21例在翻修手术时置入非侵入性可延长假体的患者,平均年龄20.4岁,平均随访70个月。结果显示平均延长51 mm,最终随访时平均残余下肢不等长为15 mm;假体生存率按Henderson标准2年为86%、5年为72%,因任何原因翻修的假体无翻修生存率2年为75%、5年为55%。作者认为该方法是改善下肢不等长的成功选择。

要点

  • 翻修时置入非侵入性可延长假体可改善下肢不等长,平均延长51 mm,最终残余不等长平均15 mm。
  • 按Henderson标准,假体生存率2年为86%、5年为72%。
  • 因任何原因翻修的假体无翻修生存率2年为75%、5年为55%。

核心结论

  • 作者经验表明,使用非侵入性可延长假体进行翻修手术是改善下肢不等长的成功选择,对于有明显下肢不等长需要翻修的患者应考虑使用。

研究设计与样本

  • 回顾性系列研究,从数据库中识别所有在翻修手术时置入非侵入性可延长假体的患者,共纳入21例(女7例,男14例),翻修时平均年龄20.4岁(范围10至41岁),平均随访70个月(范围17至128个月)。

主要发现

  • 翻修前平均短缩44 mm(范围10至100 mm),除1例患者外均进行了延长,平均延长51 mm(范围5至140 mm)。
  • 最终随访时平均残余下肢不等长为15 mm(范围1至35 mm)。
  • 2例患者发生深部假体周围感染,其中1例需截肢以根除感染,另1例需二期翻修。
  • 按Henderson标准,假体生存率2年为86%,5年为72%。
  • 因任何原因翻修(包括将可延长假体翻修为非可延长假体)的无翻修假体生存率2年为75%,5年降至55%。

关键数值与推荐

  • 翻修指征为机械失败、创伤或感染并残留下肢不等长。
  • 假体生存率按Henderson标准评估:2年86%,5年72%。
  • 因任何原因翻修的无翻修假体生存率:2年75%,5年55%。

临床怎么用

  • 作者认为,对于有明显下肢不等长需要翻修的患者,应考虑使用非侵入性可延长假体进行翻修手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The use of a noninvasive growing endoprosthesis in the management of primary bone tumours in children is well established. However, the efficacy of such a prosthesis in those requiring a revision procedure has yet to be established. The aim of this series was to present our results using extendable prostheses for the revision of previous endoprostheses. PATIENTS AND METHODS: All patients who had a noninvasive growing endoprosthesis inserted at the time of a revision procedure were identified from our database. A total of 21 patients (seven female patients, 14 male) with a mean age of 20.4 years (10 to 41) at the time of revision were included. The indications for revision were mechanical failure, trauma or infection with a residual leg-length discrepancy. The mean follow-up was 70 months (17 to 128). The mean shortening prior to revision was 44 mm (10 to 100). Lengthening was performed in all but one patient with a mean lengthening of 51 mm (5 to 140). RESULTS: The mean residual leg length discrepancy at final follow-up of 15 mm (1 to 35). Two patients developed a deep periprosthetic infection, of whom one required amputation to eradicate the infection; the other required two-stage revision. Implant survival according to Henderson criteria was 86% at two years and 72% at five years. When considering revision for any cause (including revision of the growing prosthesis to a non-growing prosthesis), revision-free implant survival was 75% at two years, but reduced to 55% at five years. CONCLUSION: Our experience indicates that revision surgery using a noninvasive growing endoprosthesis is a successful option for improving leg length discrepancy and should be considered in patients with significant leg-length discrepancy requiring a revision procedure. Cite this article: Bone Joint J 2018;100-B:370-7.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Gilg MM, Gaston CL, Jeys L, et al. The use of a non-invasive extendable prosthesis at the time of revision arthroplasty. Bone Joint J. 2018. PMID: 29589498. doi:10.1302/0301-620X.100B3.BJJ-2017-0651.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。